HTX Labs will supply immersive training technology and content to the Air Force and its Space Force military partner. Graphic courtesy of HTX Labs

HTX Labs has won a three-year, $90 million contract to provide immersive training capabilities for the Air Force and Space Force.

Under the new contract, which is set to end in September 2026, HTX Labs will supply immersive training technology and content to the Air Force and its Space Force military partner. The Houston company says the contract culminates more than five years of collaboration with the Air Force.

HTX Labs’ EMPACT cloud-based immersive training platform enables instructors and curriculum developers to create immersive lessons within EMPACT’s digital classrooms. HTX Labs says the Air Force and Space Force will retain full ownership of digital assets that are produced and will allow in-house updates of training materials.

EMPACT’s training lessons can be consumed on tablets, laptops, and virtual reality (VR) headsets.

“HTX Labs is honored to have the confidence of the Air Force per this contract that allows us to continue our collaboration with Airmen and Guardians to deliver immersive training capabilities for the warfighter,” Scott Schneider, CEO and head of growth for HTX Labs, says in a news release.

The ties between HTX Labs and the Air Force are strong.

In May, HTX Labs said it had been awarded a Small Business Innovation Research (SBIR) contract for the Tech Training Transformation Cloud project at the Air Force. The project will let airmen access, create, share, and deliver government-owned digital assets, models, simulations, and content for technical training.

Two months later, HTX Labs said retired Air Force Gen. Craig “Pulse” Wills had joined the company as a strategic adviser. During his Air Force tenure, Wills oversaw a makeover of flight training, including the introduction of extended reality (XR) training and adult learning programs.

“HTX Labs was one of the early pioneers of our Pilot Training Next effort, and they’re dedicated to meeting the needs of our warfighters,” says Wills. “Our young military members are the treasure of this nation. We owe them the very best training and tools available to make them lethal, proficient, and prepared to defend this nation and our way of life.”

Founded in 2017, HTX Labs received $3.2 million in royalty-based equity funding last year from Dallas-based Cypress Growth Capital.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

TMC launches new biotech partnership with Republic of Korea

international collaboration

Houston's Texas Medical Center has launched its new TMC Republic of Korea BioBridge.

The new partnership brings together the TMC with the Osong Medical Innovation Foundation, or KBIOHealth. The Biobridge aims to support the commercialization of Korean biotech and life science startups in the U.S., foster clinical research, and boost collaboration in the public, private and academic sectors.

Through the partnership, TMC will also develop a Global Innovators Launch Pad to foster U.S. market entry for international health care companies. Founders will be selected to participate in the 10-week program at the TMC Innovation Factory in Houston.

“Gene and cell therapies are driving biotech innovation, opening possibilities for treating diseases once thought untreatable," William McKeon, president and CEO of the Texas Medical Center, said in a news release. "Expanding biomanufacturing capacity is essential to delivering the next wave of these therapies, and partnerships with leading innovators will strengthen our efforts in Houston and internationally.”

McKeon officially signed the TMC Korea BioBridge Memorandum of Understanding with Myoung Su Lee, chairman of KBIOHealth, in South Korea in October.

"This collaboration marks a significant milestone for Korea’s biohealth ecosystem, creating a powerful bridge between Osong and Houston," Lee added in the release. "By combining KBIOHealth’s strength in research infrastructure and Korea’s biotech talent with TMC’s global network and accelerator platform, we aim to accelerate innovation and bring transformative solutions to patients worldwide.”

This is the seventh international strategic partnership for the TMC. It launched its first BioBridge with the Health Informatics Society of Australia in 2016. It launched its TMC Japan BioBridge, focused on advancing cancer treatments, last year. It also has BioBridge partnerships with the Netherlands, Ireland, Denmark and the United Kingdom.